Product Datasheet

BDTX-189

Catalog No. **BP-02010** · CAS **2414572-47-5** · Form **free base** · Physical state **solid** · Color **Off-white to light yellow** · Version **1.0** · Revision **2026-09-11**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
EGFR	**Cancer**

Molecular formula	$C_{29}H_{29}ClN_6O_4$
Molecular weight	**561.0310**

STRUCTURE



DESCRIPTION

Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity.

BIOLOGICAL ACTIVITY

In Vitro

Tuxobertinib is a masterKey inhibitor of the ERBB allosteric mutant oncogene family with antiproliferative activity (IC50<100 nM for ERBB allosteric mutant oncogene family).

In Vivo

Tuxobertinib (0-100 mg/kg; p.o.; daily for 15 dyas) shows dose-dependent tumor growth inhibition and regression in in athymic nude mice bearing HER2 S310F Ba/F3 allograft tumors.

? Tuxobertinib (1-50 mg/kg.p.o.; daily for 15 days) shows dose-dependent tumor growth inhibition and regression in athymic nude mice bearing CUTO-14 PDX tumors that express the EGFR mutation EGFR ASV.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Elizabeth Buck, et al. BDTX-189, a Potent and Selective Inhibitor of Allosteric EGFR and HER2 Oncogenic Mutations.